Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Phosphoric Acid→

Phosphoric Acid Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
7664-38-2
Molecular formula
H3PO4
Molecular weight
97.9952 g/mol
Drug class
Inorganic mineral acidpharmaceutical pH-adjusting and acidifying excipient in many formulations
Mechanism of action
Dissociates in aqueous systems and adjusts formulation pH through its acid-base equilibria. Its function in a specific product depends on concentration, buffering system and formulation; no single therapeutic mechanism can be assigned from the catalogue name alone.

Sources: USP–NF — Phosphoric Acid (compendial substance) · PubChem — Phosphoric acid · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Phosphoric Acid Environmental Risk Assessment (ERA) (the Phosphoric Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.